Literature DB >> 2849111

Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160.

R L Willey1, J S Bonifacino, B J Potts, M A Martin, R D Klausner.   

Abstract

The synthesis and processing of the human immunodeficiency virus 1 (HIV-1) envelope precursor glycoprotein gp 160 was studied in an infected CD4+ lymphocytic cell line. Surprisingly, only a small percentage (5-15%) of gp160 is cleaved to produce the mature gp120 component. Intracellular sorting results in the transfer of most uncleaved gp160 to lysosomes, where it is degraded, while gp120 is transported to the cell surface and subsequently secreted. Cleavage of gp160 to generate gp120 occurs intracellularly and can be inhibited by NH4Cl. Taken together, these results indicate that intracellular cleavage of gp160 determines the intracellular transport and survival of the envelope glycoproteins necessary to produce infectious virus.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2849111      PMCID: PMC282803          DOI: 10.1073/pnas.85.24.9580

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Cellular maturation of oncornavirus glycoproteins: topological arrangement of precursor and product forms in cellular membranes.

Authors:  O N Witte; A Tsukamoto-Adey; I L Weissman
Journal:  Virology       Date:  1977-02       Impact factor: 3.616

2.  Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III.

Authors:  J S Allan; J E Coligan; F Barin; M F McLane; J G Sodroski; C A Rosen; W A Haseltine; T H Lee; M Essex
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

3.  The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors.

Authors:  R J Mervis; N Ahmad; E P Lillehoj; M G Raum; F H Salazar; H W Chan; S Venkatesan
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

4.  Presence of murine leukemia virus envelope proteins gp70 and p15(E) in a common polyprotein of infected cells.

Authors:  N G Famulari; D L Buchhagen; H D Klenk; E Fleissner
Journal:  J Virol       Date:  1976-11       Impact factor: 5.103

5.  Oligosaccharide modifications and the site of processing of gPr92env, the precursor for the viral glycoproteins of Rous sarcoma virus.

Authors:  J V Bosch; R T Schwarz; A Ziemiecki; R R Friis
Journal:  Virology       Date:  1982-05       Impact factor: 3.616

Review 6.  The role of viral glycoproteins in adsorption, penetration, and pathogenicity of viruses.

Authors:  P W Choppin; A Scheid
Journal:  Rev Infect Dis       Date:  1980 Jan-Feb

7.  Processing of gPr92env, the precursor to the glycoproteins of Rous sarcoma virus: use of inhibitors of oligosaccharide trimming and glycoprotein transport.

Authors:  J V Bosch; R T Schwarz
Journal:  Virology       Date:  1984-01-15       Impact factor: 3.616

8.  Accumulation of amino acids by lysosomes incubated with amino acid methyl esters.

Authors:  J P Reeves
Journal:  J Biol Chem       Date:  1979-09-25       Impact factor: 5.157

9.  Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages.

Authors:  B Poole; S Ohkuma
Journal:  J Cell Biol       Date:  1981-09       Impact factor: 10.539

10.  Mutations of the Rous sarcoma virus env gene that affect the transport and subcellular location of the glycoprotein products.

Authors:  J W Wills; R V Srinivas; E Hunter
Journal:  J Cell Biol       Date:  1984-12       Impact factor: 10.539

View more
  210 in total

1.  Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.

Authors:  R W Sanders; L Schiffner; A Master; F Kajumo; Y Guo; T Dragic; J P Moore; J M Binley
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus.

Authors:  A Ono; E O Freed
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity.

Authors:  R E Kiernan; A Ono; E O Freed
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

4.  Mutational analysis of conserved domains within the cytoplasmic tail of gp41 from human immunodeficiency virus type 1: effects on glycoprotein incorporation and infectivity.

Authors:  S C Piller; J W Dubay; C A Derdeyn; E Hunter
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Cellular membrane-binding ability of the C-terminal cytoplasmic domain of human immunodeficiency virus type 1 envelope transmembrane protein gp41.

Authors:  S S Chen; S F Lee; C T Wang
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins.

Authors:  Christoph Grundner; Tajib Mirzabekov; Joseph Sodroski; Richard Wyatt
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

7.  Identification of two sequences in the cytoplasmic tail of the human immunodeficiency virus type 1 envelope glycoprotein that inhibit cell surface expression.

Authors:  A Bültmann; W Muranyi; B Seed; J Haas
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 8.  Recent strategies targeting HIV glycans in vaccine design.

Authors:  Satoru Horiya; Iain S MacPherson; Isaac J Krauss
Journal:  Nat Chem Biol       Date:  2014-12       Impact factor: 15.040

9.  Stabilization of HIV-1 gp120-CD4 receptor complex through targeted interchain disulfide exchange.

Authors:  Nichole Cerutti; Barry V Mendelow; Grant B Napier; Maria A Papathanasopoulos; Mark Killick; Makobetsa Khati; Wendy Stevens; Alexio Capovilla
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

10.  Reevaluation of the requirement for TIP47 in human immunodeficiency virus type 1 envelope glycoprotein incorporation.

Authors:  Mary Ann Checkley; Benjamin G Luttge; Peter Y Mercredi; Sampson K Kyere; Justin Donlan; Tsutomu Murakami; Michael F Summers; Simon Cocklin; Eric O Freed
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.